The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Oct 12, 2026
Snapshot (as of Oct 12, 2026): Quest Diagnostics Incorporated (DGX) pays a $3.32 annual dividend ($0.86 quarterly), yielding 1.49% at $230.97/share. Next ex-dividend date 2026-10-06. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 1.49%
Annual Dividend: $3.32 per share
Payout Ratio: 26.1%
Ex-Dividend Date: 2026-10-06
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 23
Quest Diagnostics Incorporated dividend investors are looking at a company that processes routine and advanced clinical testing across a national network of laboratories and patient service centers. The current yield is 1.49%, with trailing twelve-month payments of $3.32 per share paid quarterly. The next ex-dividend date is October 6, 2026, with the last declared payment at $0.86 per share. A beta of 0.54 makes DGX stock notably less volatile than the broader market, which suits investors who prioritize steadiness over high current income.
Quest Diagnostics Incorporated pays out 26.1% of earnings as dividends, a payout ratio classified as conservative (below 40%). That low payout reflects a business built on recurring demand: diagnostic testing services, from routine bloodwork to specialized cancer and neurology panels, generate steady utilization across physicians, hospitals, health plans, and employers. Quest Diagnostics Incorporated dividend safety benefits from that breadth of customers and service types, which limits dependence on any single revenue stream. The most data-supported pressure point is the two-year consecutive increase streak, which is short and leaves the growth commitment less established than longer-tenured payers.
Quest Diagnostics Incorporated dividend history shows a CAGR of 15.9% per year from 2011 to 2025. Per-share payments grew from $0.40 to $3.15 over that window (2026 data is partial and excluded from the CAGR calculation). The largest single-year jump was 76.5% in 2013, though the history also contains at least one year-over-year decline exceeding 5%, specifically the drop from $3.26 in 2022 to $2.79 in 2023. That dip matters: the 15.9% long-run CAGR is real, but the path was not linear.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | -1.1% | $3.26 (2022) | $3.15 (2025) |
| 5-Year | +7.3% | $2.21 (2020) | $3.15 (2025) |
| 10-Year | +7.9% | $1.47 (2015) | $3.15 (2025) |
DGX stock fits growth-and-income investors who want dividend expansion more than immediate yield. At 1.49%, the current yield is classified as low (below 2%) and sits below the 5-year average of 1.82%, meaning buyers today are accepting less current income than the stock has historically offered. The 26.1% payout ratio leaves substantial room for future increases, and the 15.9% long-run growth rate is the defining trait here. The trade-off is clear: Quest Diagnostics Incorporated delivers a conservative, well-covered payout with a strong historical growth rate, but investors who need meaningful income today will find the current yield thin.
| Payment Date | Amount per Share |
|---|---|
| 2026-10-06 | $0.8600 |
| 2026-07-08 | $0.8600 |
| 2026-04-06 | $0.8600 |
| 2026-01-13 | $0.8000 |
| 2025-10-03 | $0.8000 |
| 2025-07-07 | $0.8000 |
| 2025-04-07 | $0.8000 |
| 2025-01-14 | $0.7500 |
| 2024-10-04 | $0.7500 |
| 2024-07-08 | $0.7500 |
| Year | Total Dividends |
|---|---|
| 2026 | $3.3800 |
| 2025 | $3.1500 |
| 2024 | $2.9600 |
| 2023 | $2.7900 |
| 2022 | $3.2600 |
Project income from DGX with the DGX dividend calculator or track your full portfolio with the dividend tracker.